Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injectables licensed in the UK are once-weekly, self-administered medicines — tirzepatide (Mounjaro) and semaglutide (Wegovy) — that work by acting on gut hormones to reduce appetite and slow gastric emptying. They are prescription-only medicines; a prescriber assesses clinical suitability before any treatment begins. If you've arrived here feeling overwhelmed by competing claims online, that reaction is entirely reasonable: this area attracts a lot of noise. What follows is the evidence, plainly stated.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most persistent misconception about weight loss injectables is that they sit somewhere between a supplement and a cosmetic treatment, something you pick up, use for a few weeks and stop. They do not. Tirzepatide and semaglutide are classified as Prescription-Only Medicines under UK law, which means a registered prescriber must assess whether they are clinically appropriate for you before a single pen is dispensed. That assessment is not a formality; it considers your BMI, existing health conditions, current medicines, and whether this class of drug is safe for you specifically.
The MHRA has been unambiguous about the risks of bypassing that step. Counterfeit pens sold on social media and from unverified online sellers have, in documented cases, contained insulin rather than the stated active ingredient, with serious consequences for the people who used them. If you are researching where to buy weight loss injections in the UK, verifying that any pharmacy you use is registered on the GPhC register at pharmacyregulation.org is the single most important safety check you can do.
The licensed route is not more complicated, it is simply a proper clinical consultation, a prescriber's review, and then the medicine dispensed from a pharmacy in an authenticated supply chain.
Both licensed injectables mimic hormones your gut releases after eating. Semaglutide targets the GLP-1 receptor, which signals fullness to the brain and slows how quickly the stomach empties. Tirzepatide does the same and also activates the GIP receptor, making it the only dual-agonist weight management medicine currently licensed in the UK. You can read more about how each medicine differs on our injectable weight loss drug overview.
Treatment always starts at the lowest strength (2.5 mg for tirzepatide, 0.25 mg for semaglutide) not because those doses drive meaningful weight loss, but because starting low gives your body time to adjust and significantly reduces early nausea. The prescriber then titrates upward, typically in four-week steps, to the highest dose you tolerate well. The titration schedule is set by your prescriber and the Patient Information Leaflet; nobody should be adjusting doses based on a forum recommendation.
In clinical trials, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks in SURMOUNT-1, a trial of 2,539 adults with obesity. Semaglutide 2.4 mg produced around 15% average loss over 68 weeks in the STEP 1 trial. Both figures come from participants following a reduced-calorie diet and increased activity alongside the medicine, the injections support lifestyle change, they do not replace it. The SURMOUNT-1 paper in the New England Journal of Medicine gives the full methodology for anyone who wants to read the source directly.
The side-effect profile of weight loss injectables is dominated by the gastrointestinal system: nausea, loose stools, constipation, indigestion and burping are the most reported. Most people find these are worst in the early weeks and after each dose step up, then ease. Staying well hydrated, eating smaller portions more slowly, and avoiding very fatty or spicy meals during the adjustment period all help, though your prescriber is the right person to advise on your specific situation.
Some effects need prompt medical attention. The NHS tirzepatide page lists red flags clearly: severe, persistent stomach pain that reaches through to the back (which can signal pancreatitis), signs of a serious allergic reaction, and symptoms of gallbladder problems. These are uncommon, but the rule is simple, if in doubt, contact a clinician the same day rather than waiting.
Women using oral contraceptives starting tirzepatide should add a non-oral method (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce pill absorption. The equivalent concern has not been demonstrated for semaglutide. Our guide to weight loss injections covers practical considerations including contraception, storage and injection technique in more detail.
The private licensed eligibility criteria, set by the medicines' marketing authorisations, cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI is a starting point, not the whole picture; prescribers weigh the full clinical assessment before approving treatment.
NHS access is narrower and phased. NICE's appraisal of tirzepatide (TA1026) recommends it for BMI 35 and above alongside specific comorbidities, rolled out in cohorts from June 2025. Wegovy on the NHS is routed through specialist weight management services with typically long waiting lists. For people who meet the private criteria but cannot access NHS treatment (or simply prefer not to wait) a regulated private pharmacy is the lawful alternative. Our treatment page explains what a consultation with our prescribers covers and how the process works from start to delivery.
Every pen dispensed by a GPhC-registered pharmacy arrives from the licensed UK supply chain. That matters because it is the only way to be certain the product in your hands is genuine. If you are still building an understanding of how a weight loss injectable fits into a broader treatment plan, that page brings together the key clinical context in one place. Curious about which specific injectables are available and how they compare? Our overview of weight loss injectable names sets out the licensed options clearly. For the practical side of using a pen (injection sites, technique and what to do with used needles) the injectable pen guide is worth a read before you start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.